Mandate

Vinge advises Adelis Equity Partners on the establishment of Adelis Equity Partners Fund IV

March 03, 2025 Private Funds

Vinge has advised Adelis Equity Partners on the establishment of Adelis’ fourth flagship fund: Adelis Equity Partners Fund IV.

The fund, which was significantly oversubscribed, held its final closing on 28 February 2025 after having raised commitments of EUR 1.6 billion from an investor base consisting of leading pension funds, foundations and fund-of-funds across Europe and North America, and from the Adelis team. The fund raise entails a more than 50% increase in commitments relative to the predecessor fund, Adelis Equity Partners Fund III. Since its commencement in 2013, Adelis invests in well-positioned companies in the Nordic and DACH regions and has to date made 45 platform investments and more than 260 add-on acquisitions.

Vinge’s team primarily consisted of Mattias Schömer, Nils Unckel, Martin Cronsioe, Ulf Nilsson, Mikaela Reinhammar, Anton Sjökvist, Emelie Svanberg, Tobias Onegård Karlsson, Viktoria Wnuk, Rebecka Margolin, Saga Meyer Viklund and Emelie Zingmark.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025